Supernus Pharmaceuticals: Funding, Investors & Team (Sep 2026)
We are a pharmaceutical firm dedicated to creating and marketing medications to treat disorders of the central nervous system (CNS). During the past 30 years, we have developed our substantial product development expertise as a separate development organisation, a US subsidiary of Shire plc, and, most recently, as Supernus Pharmaceuticals Inc. We use our own specialty sales team to promote our drugs in the United States, and we look for strategic partnerships with other pharmaceutical firms to licence our treatments abroad. For the treatment of attention deficit/hyperactivity disorder (ADHD) in children aged 6 to 17, we provide Qelbree® (viloxazine extended-release).
Supernus Pharmaceuticals has raised $150M across 1 funding round on record, the most recent an undisclosed round of $150M announced in Feb 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Supernus Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Feb 2023.
Supernus Pharmaceuticals Funding Rounds
Supernus Pharmaceuticals Founders and Leadership Team
No contact details are on record for this team yet.
Supernus Pharmaceuticals Funding Compared to Other Biotechnology Startups
Supernus Pharmaceuticals' latest round of $150M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Supernus Pharmaceuticals in Biotechnology and Rockville
Companies Similar to Supernus Pharmaceuticals
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Supernus Pharmaceuticals Funding FAQs
What does Supernus Pharmaceuticals do?
We are a pharmaceutical firm dedicated to creating and marketing medications to treat disorders of the central nervous system (CNS). During the past 30 years, we have developed our substantial product development expertise as a separate development organisation, a US subsidiary of Shire plc, and, most recently, as Supernus Pharmaceuticals Inc. We use our own specialty sales team to promote our drugs in the United States, and we look for strategic partnerships with other pharmaceutical firms to licence our treatments abroad. For the treatment of attention deficit/hyperactivity disorder (ADHD) in children aged 6 to 17, we provide Qelbree® (viloxazine extended-release).
How much funding has Supernus Pharmaceuticals raised?
Supernus Pharmaceuticals has raised $150M across 1 round on record. The most recent is an undisclosed round of $150M announced in Feb 2023.
When did Supernus Pharmaceuticals last raise funding?
Supernus Pharmaceuticals' most recent funding round on record is an undisclosed round of $150M, announced in Feb 2023.
Who is the CEO of Supernus Pharmaceuticals?
Jack A Khattar is listed as CEO at Supernus Pharmaceuticals.
Where is Supernus Pharmaceuticals headquartered?
Supernus Pharmaceuticals is based in Rockville, Maryland, United States.
How many employees does Supernus Pharmaceuticals have?
Supernus Pharmaceuticals is in the 501-1000 employee band.
How does Supernus Pharmaceuticals' funding compare to other Biotechnology startups?
Supernus Pharmaceuticals' latest round of $150M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Supernus Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Supernus Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.